Literature DB >> 22770891

CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits.

Se-Yeong Oh1, Hyun Jung Kang, Young Sook Kim, Hyunggee Kim, Young Chang Lim.   

Abstract

CD44 is generally accepted as a surrogate marker for head and neck squamous carcinoma cancer stem cells (HNSC CSCs) and only CD44+ HNSC cells have tumour initiating capacity. However, a recent report suggested that CSCs themselves might be heterogenous due to various genetic alterations. Here, we compared in vitro stem-like cell characteristics, chemoresistance and in vivo tumour formation capacity of CD44+ and CD44- HNSC cells obtained from primary HNSC patient specimens. CD44- HNSC spheroid cells generated spheroid cells again after seeding of single-dissociated spheroid CD44- HNSC cells. Immunocytochemistry assays revealed that various stem cell markers, including octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2) and nestin were up-regulated in CD44- spheroid cells, similar to CD44+ spheroid cells. Furthermore, CD44- spheroid cells appeared to be chemoresistant to cisplatin and showed increased levels of ABCG2, similar to CD44+ spheroid cells. Of most interest, as few as 1000 CD44- spheroid cells were able to give rise to tumours in nude mice. The collective data indicate that the cell surface marker CD44 cannot be used as a selective marker of spheroid-forming, tumour-initiating or chemoresistant cell populations, and further indicate the limitation of current HNSC CSC identification methods using the CD44 cell surface marker.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22770891     DOI: 10.1016/j.ejca.2012.06.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

1.  Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies.

Authors:  Amy S Codd; Saly Al-Taei; Zsuzsanna Tabi
Journal:  Ann Transl Med       Date:  2016-10

2.  Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.

Authors:  Osama A Elkashty; Ghada Abu Elghanam; Xinyun Su; Younan Liu; Peter J Chauvin; Simon D Tran
Journal:  Carcinogenesis       Date:  2020-06-17       Impact factor: 4.944

Review 3.  Strategies for isolating and enriching cancer stem cells: well begun is half done.

Authors:  Jiang-Jie Duan; Wen Qiu; Sen-Lin Xu; Bin Wang; Xian-Zong Ye; Yi-Fang Ping; Xia Zhang; Xiu-Wu Bian; Shi-Cang Yu
Journal:  Stem Cells Dev       Date:  2013-05-09       Impact factor: 3.272

4.  Prognostic utility of SOX2, STAT3, and CD44high/CD24low expression in penile cancer.

Authors:  Felipe Dubourcq de Barros; Leuridan Cavalcante Torres; Carolline Araujo; Felipe da Silva Marinho; Beatriz Cavalcanti Dubourcq; Luís Cavalcanti Dubourcq; Gustavo Cardoso Guimarães
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-01       Impact factor: 4.322

Review 5.  Searching for prostate cancer stem cells: markers and methods.

Authors:  Benjamin Sharpe; Mark Beresford; Rebecca Bowen; John Mitchard; Andrew D Chalmers
Journal:  Stem Cell Rev Rep       Date:  2013-10       Impact factor: 5.739

Review 6.  Cancer stem cells in human digestive tract malignancies.

Authors:  Fatemeh B Rassouli; Maryam M Matin; Morvarid Saeinasab
Journal:  Tumour Biol       Date:  2015-10-07

7.  CD271 defines a stem cell-like population in hypopharyngeal cancer.

Authors:  Takayuki Imai; Keiichi Tamai; Sayuri Oizumi; Kyoko Oyama; Kazunori Yamaguchi; Ikuro Sato; Kennichi Satoh; Kazuto Matsuura; Shigeru Saijo; Kazuo Sugamura; Nobuyuki Tanaka
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

8.  Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer.

Authors:  Takeichiro Aso; Mioko Matsuo; Hideyuki Kiyohara; Kenichi Taguchi; Fumihide Rikimaru; Mototsugu Shimokawa; Yuichi Segawa; Yuichiro Higaki; Hirohito Umeno; Tadashi Nakashima; Muneyuki Masuda
Journal:  PLoS One       Date:  2015-03-09       Impact factor: 3.240

Review 9.  Cancer stem cells accountability in progression of head and neck squamous cell carcinoma: the most recent trends!

Authors:  Samapika Routray; Neeta Mohanty
Journal:  Mol Biol Int       Date:  2014-02-19

10.  Small molecule antagonist of the bone morphogenetic protein type I receptors suppresses growth and expression of Id1 and Id3 in lung cancer cells expressing Oct4 or nestin.

Authors:  Elaine Langenfeld; Malik Deen; Emmanuel Zachariah; John Langenfeld
Journal:  Mol Cancer       Date:  2013-10-26       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.